These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

911 related articles for article (PubMed ID: 15128775)

  • 1. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis.
    Bharti AC; Takada Y; Aggarwal BB
    J Immunol; 2004 May; 172(10):5940-7. PubMed ID: 15128775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway.
    Ahn KS; Sethi G; Chaturvedi MM; Aggarwal BB
    Int J Cancer; 2008 Oct; 123(8):1733-40. PubMed ID: 18688862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1'-Acetoxychavicol acetate inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-kappaB activation.
    Ichikawa H; Murakami A; Aggarwal BB
    Mol Cancer Res; 2006 Apr; 4(4):275-81. PubMed ID: 16603641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
    Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
    J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guggulsterone inhibits osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand and by tumor cells by suppressing nuclear factor-kappaB activation.
    Ichikawa H; Aggarwal BB
    Clin Cancer Res; 2006 Jan; 12(2):662-8. PubMed ID: 16428513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways.
    Zhang YH; Heulsmann A; Tondravi MM; Mukherjee A; Abu-Amer Y
    J Biol Chem; 2001 Jan; 276(1):563-8. PubMed ID: 11032840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage.
    Khapli SM; Mangashetti LS; Yogesha SD; Wani MR
    J Immunol; 2003 Jul; 171(1):142-51. PubMed ID: 12816992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling.
    Rahman MM; Bhattacharya A; Fernandes G
    J Lipid Res; 2006 Aug; 47(8):1739-48. PubMed ID: 16702601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis.
    Kimachi K; Kajiya H; Nakayama S; Ikebe T; Okabe K
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Mar; 383(3):297-308. PubMed ID: 21225243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors.
    Sugatani T; Alvarez UM; Hruska KA
    J Cell Biochem; 2003 Sep; 90(1):59-67. PubMed ID: 12938156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diosgenin inhibits osteoclastogenesis, invasion, and proliferation through the downregulation of Akt, I kappa B kinase activation and NF-kappa B-regulated gene expression.
    Shishodia S; Aggarwal BB
    Oncogene; 2006 Mar; 25(10):1463-73. PubMed ID: 16331273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products.
    Shishodia S; Gutierrez AM; Lotan R; Aggarwal BB
    Cancer Res; 2005 Oct; 65(20):9555-65. PubMed ID: 16230421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis.
    Zhang Z; Jimi E; Bothwell AL
    J Immunol; 2003 Oct; 171(7):3620-6. PubMed ID: 14500659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetyl-11-keto-beta-boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-kappa B and NF-kappa B-regulated gene expression.
    Takada Y; Ichikawa H; Badmaev V; Aggarwal BB
    J Immunol; 2006 Mar; 176(5):3127-40. PubMed ID: 16493072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand.
    Lam J; Takeshita S; Barker JE; Kanagawa O; Ross FP; Teitelbaum SL
    J Clin Invest; 2000 Dec; 106(12):1481-8. PubMed ID: 11120755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoclast differentiation by RANKL requires NF-kappaB-mediated downregulation of cyclin-dependent kinase 6 (Cdk6).
    Ogasawara T; Katagiri M; Yamamoto A; Hoshi K; Takato T; Nakamura K; Tanaka S; Okayama H; Kawaguchi H
    J Bone Miner Res; 2004 Jul; 19(7):1128-36. PubMed ID: 15176996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha.
    Chaisson ML; Branstetter DG; Derry JM; Armstrong AP; Tometsko ME; Takeda K; Akira S; Dougall WC
    J Biol Chem; 2004 Dec; 279(52):54841-8. PubMed ID: 15485831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
    Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
    J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.